EA201590451A1 - Способ лечения меланомы с применением вируса простого герпеса и ингибитора иммунной контрольной точки - Google Patents
Способ лечения меланомы с применением вируса простого герпеса и ингибитора иммунной контрольной точкиInfo
- Publication number
- EA201590451A1 EA201590451A1 EA201590451A EA201590451A EA201590451A1 EA 201590451 A1 EA201590451 A1 EA 201590451A1 EA 201590451 A EA201590451 A EA 201590451A EA 201590451 A EA201590451 A EA 201590451A EA 201590451 A1 EA201590451 A1 EA 201590451A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- virus
- control point
- treating melanoma
- immune control
- inhibitor immune
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/245—Herpetoviridae, e.g. herpes simplex virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/76—Viruses; Subviral particles; Bacteriophages
- A61K35/763—Herpes virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/53—Colony-stimulating factor [CSF]
- C07K14/535—Granulocyte CSF; Granulocyte-macrophage CSF
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14311—Parvovirus, e.g. minute virus of mice
- C12N2750/14341—Use of virus, viral particle or viral elements as a vector
- C12N2750/14343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2799/00—Uses of viruses
- C12N2799/02—Uses of viruses as vector
- C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
- C12N2799/025—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a parvovirus
Abstract
Изобретение относится к способам лечения меланомы с применением вируса простого герпеса в комбинации с ингибитором иммунной контрольной точки.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261694963P | 2012-08-30 | 2012-08-30 | |
US201361846147P | 2013-07-15 | 2013-07-15 | |
PCT/US2013/057542 WO2014036412A2 (en) | 2012-08-30 | 2013-08-30 | A method for treating melanoma using a herpes simplex virus and an immune checkpoint inhibitor |
Publications (1)
Publication Number | Publication Date |
---|---|
EA201590451A1 true EA201590451A1 (ru) | 2016-05-31 |
Family
ID=49162279
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EA201590451A EA201590451A1 (ru) | 2012-08-30 | 2013-08-30 | Способ лечения меланомы с применением вируса простого герпеса и ингибитора иммунной контрольной точки |
Country Status (12)
Country | Link |
---|---|
US (2) | US10034938B2 (ru) |
EP (3) | EP3981791A1 (ru) |
JP (2) | JP6457940B2 (ru) |
KR (2) | KR102204525B1 (ru) |
CN (2) | CN104704002B (ru) |
AU (3) | AU2013308595C1 (ru) |
CA (1) | CA2881851C (ru) |
EA (1) | EA201590451A1 (ru) |
ES (1) | ES2871910T3 (ru) |
HK (1) | HK1211601A1 (ru) |
PT (1) | PT3381942T (ru) |
WO (1) | WO2014036412A2 (ru) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RU2802962C2 (ru) * | 2017-10-27 | 2023-09-05 | МЕРК ШАРП И ДОУМ ЭлЭлСи | Композиции и способы лечения рака печени |
Families Citing this family (46)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PT3381942T (pt) | 2012-08-30 | 2021-05-24 | Amgen Inc | Método para o tratamento do melanoma que utiliza um vírus herpes simplex e um inibidor de checkpoint imunitário |
US10350275B2 (en) * | 2013-09-21 | 2019-07-16 | Advantagene, Inc. | Methods of cytotoxic gene therapy to treat tumors |
JP6508785B2 (ja) | 2013-10-25 | 2019-05-08 | ファーマサイクリックス エルエルシー | ブルトンチロシンキナーゼ阻害剤および免疫療法を使用する処置 |
US10329556B2 (en) | 2014-05-13 | 2019-06-25 | Bioatla, Llc | Conditionally active biological proteins |
CA2951259A1 (en) | 2014-06-06 | 2015-12-10 | Flexus Biosciences, Inc. | Immunoregulatory agents |
US10765710B2 (en) * | 2014-07-16 | 2020-09-08 | Institut Gustave-Roussy | Combination of oncolytic virus with immune checkpoint modulators |
US9539245B2 (en) | 2014-08-07 | 2017-01-10 | Aerpio Therapeutics, Inc. | Combination of immunotherapies with activators of Tie-2 |
CA2964155A1 (en) | 2014-10-10 | 2016-04-14 | Idera Pharmaceuticals, Inc. | Treatment of cancer using tlr9 agonist with checkpoint inhibitors |
KR102589557B1 (ko) * | 2014-10-21 | 2023-10-16 | 시클론 파마수티컬 인터내셔널 리미티드 | 면역 자극인자를 이용한 암의 치료 |
AR102537A1 (es) | 2014-11-05 | 2017-03-08 | Flexus Biosciences Inc | Agentes inmunomoduladores |
UY36390A (es) | 2014-11-05 | 2016-06-01 | Flexus Biosciences Inc | Compuestos moduladores de la enzima indolamina 2,3-dioxigenasa (ido), sus métodos de síntesis y composiciones farmacéuticas que los contienen |
US11242319B2 (en) | 2014-11-05 | 2022-02-08 | Flexus Biosciences, Inc. | Immunoregulatory agents |
WO2016183532A1 (en) | 2015-05-13 | 2016-11-17 | Synlogic, Inc. | Bacteria engineered to treat a disease or disorder |
BR112017013009A2 (pt) * | 2014-12-18 | 2018-06-26 | Amgen Inc | formulação de vírus herpes simplex congelada estável |
AU2016229408A1 (en) | 2015-02-25 | 2017-09-14 | Memorial Sloan-Kettering Cancer Center | Use of inactivated nonreplicating modified vaccinia virus ankara (mva) as monoimmunotherapy or in combination with immune checkpoint blocking agents for solid tumors |
WO2016140714A1 (en) * | 2015-03-05 | 2016-09-09 | The General Hospital Corporation | Novel compositions and uses of metformin agents |
CA2982896A1 (en) * | 2015-04-17 | 2016-10-20 | Memorial Sloan Kettering Cancer Center | Use of modified vaccinia ankara virus (mva) or mva with a deletion of virulence factor e8 as immunotherapeutic agent against solid tumors |
WO2017004421A1 (en) * | 2015-06-30 | 2017-01-05 | The Trustees Of The University Of Pennsylvania | Resiquimod topical and injectable compositions for the treatment of neoplastic skin conditions |
EP3324988B1 (en) * | 2015-07-20 | 2021-03-03 | Virttu Biologics Limited | Use of oncolytic herpes simplex virus in combination with immune checkpoint inhibitor, in the treatment of cancer |
JP2018532810A (ja) | 2015-11-07 | 2018-11-08 | マルチビア インコーポレイテッド | がんの処置のための腫瘍抑制因子遺伝子治療および免疫チェックポイント治療を含む組成物 |
WO2017106656A1 (en) | 2015-12-17 | 2017-06-22 | Novartis Ag | Antibody molecules to pd-1 and uses thereof |
EP3805376A1 (en) | 2016-01-08 | 2021-04-14 | Replimune Limited | Engineered virus |
EP3943115A1 (en) | 2016-01-08 | 2022-01-26 | Momotaro-Gene Inc. | A combination therapy using reic/dkk-3 gene and a checkpoint inhibitor |
BR112018016949A2 (pt) | 2016-02-25 | 2019-01-08 | Memorial Sloan Kettering Cancer Center | vírus vaccinia atenuado competente em relação à replicação como deleção de timidina quinase com ou sem a expressão de flt3l ou gm-csf humano para imunoterapia de câncer |
EP3419662A4 (en) | 2016-02-25 | 2019-09-18 | Memorial Sloan Kettering Cancer Center | RECOMBINANT MVA OR MVADELE3L EXPRESSING FLT3L HUMAN AND THEIR USE AS IMMUNOTHERAPEUTIC AGENTS AGAINST SOLID TUMORS |
BR112018068461A2 (pt) | 2016-03-15 | 2019-01-22 | Mersana Therapeutics Inc | conjugado, composição farmacêutica, métodos para preparação de um conjugado e para alívio de um sintoma de um câncer. |
JP7197370B2 (ja) * | 2016-06-17 | 2022-12-27 | ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア | がんの予防および/または治療のための化合物、組成物および方法 |
JP6910653B2 (ja) | 2016-07-01 | 2021-07-28 | 国立大学法人東北大学 | 免疫チェックポイント阻害薬使用における免疫関連副作用の予測方法 |
PT3293201T (pt) | 2016-09-12 | 2020-12-07 | Targovax Oy | Combinação de adenovírus e inibidores de ponto de verificação para tratamento do cancro |
WO2018075447A1 (en) * | 2016-10-19 | 2018-04-26 | The Trustees Of Columbia University In The City Of New York | Combination of braf inhibitor, talimogene laherparepvec, and immune checkpoint inhibitor for use in the treatment cancer (melanoma) |
US11135307B2 (en) | 2016-11-23 | 2021-10-05 | Mersana Therapeutics, Inc. | Peptide-containing linkers for antibody-drug conjugates |
CA3046961A1 (en) | 2016-12-12 | 2018-06-21 | Multivir Inc. | Methods and compositions comprising viral gene therapy and an immune checkpoint inhibitor for treatment and prevention of cancer and infectious diseases |
TW201834697A (zh) | 2017-02-28 | 2018-10-01 | 美商梅爾莎納醫療公司 | Her2標靶抗體-藥物結合物之組合療法 |
US20200009204A1 (en) * | 2017-03-15 | 2020-01-09 | Amgen Inc. | Use of oncolytic viruses, alone or in combination with a checkpoint inhibitor, for the treatment of cancer |
EA201992575A1 (ru) | 2017-04-28 | 2020-04-13 | Мерк Шарп И Доум Корп. | Биомаркеры для терапии рака |
WO2018209315A1 (en) | 2017-05-12 | 2018-11-15 | Memorial Sloan Kettering Cancer Center | Vaccinia virus mutants useful for cancer immunotherapy |
CN107354136A (zh) * | 2017-06-15 | 2017-11-17 | 杭州睿可特生物科技有限公司 | 重组单纯疱疹病毒及其制备方法和应用 |
MX2020003388A (es) | 2017-10-27 | 2020-08-03 | Merck Sharp & Dohme | Composiciones y metodos para tratar cancer hepatico. |
WO2019104289A1 (en) | 2017-11-27 | 2019-05-31 | Mersana Therapeutics, Inc. | Pyrrolobenzodiazepine antibody conjugates |
EP3727463A1 (en) | 2017-12-21 | 2020-10-28 | Mersana Therapeutics, Inc. | Pyrrolobenzodiazepine antibody conjugates |
US20210094991A1 (en) | 2018-03-19 | 2021-04-01 | Multivir Inc. | Methods and compositions comprising tumor suppressor gene therapy and cd122/cd132 agonists for the treatment of cancer |
CN108635380A (zh) * | 2018-04-13 | 2018-10-12 | 北京唯源立康生物科技有限公司 | 重组溶瘤病毒组合物及其在制备用于***的药物中的应用 |
CN116870165A (zh) * | 2018-08-17 | 2023-10-13 | 北京奥源和力生物技术有限公司 | 用于治疗癌症的组合及其治疗用途 |
EP3873534A1 (en) | 2018-10-29 | 2021-09-08 | Mersana Therapeutics, Inc. | Cysteine engineered antibody-drug conjugates with peptide-containing linkers |
TW202102543A (zh) * | 2019-03-29 | 2021-01-16 | 美商安進公司 | 溶瘤病毒在癌症新輔助療法中之用途 |
WO2021113644A1 (en) | 2019-12-05 | 2021-06-10 | Multivir Inc. | Combinations comprising a cd8+ t cell enhancer, an immune checkpoint inhibitor and radiotherapy for targeted and abscopal effects for the treatment of cancer |
Family Cites Families (29)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6051227A (en) | 1995-07-25 | 2000-04-18 | The Regents Of The University Of California, Office Of Technology Transfer | Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling |
US5811097A (en) | 1995-07-25 | 1998-09-22 | The Regents Of The University Of California | Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling |
US5855887A (en) | 1995-07-25 | 1999-01-05 | The Regents Of The University Of California | Blockade of lymphocyte down-regulation associated with CTLA-4 signaling |
US6207157B1 (en) | 1996-04-23 | 2001-03-27 | The United States Of America As Represented By The Department Of Health And Human Services | Conjugate vaccine for nontypeable Haemophilus influenzae |
US6682736B1 (en) | 1998-12-23 | 2004-01-27 | Abgenix, Inc. | Human monoclonal antibodies to CTLA-4 |
US7605238B2 (en) | 1999-08-24 | 2009-10-20 | Medarex, Inc. | Human CTLA-4 antibodies and their uses |
KR100996759B1 (ko) | 1999-08-24 | 2010-11-25 | 메다렉스, 인코포레이티드 | 인간 씨티엘에이-4 항체 및 그의 용도 |
WO2001053505A2 (en) | 2000-01-21 | 2001-07-26 | Biovex Limited | Herpes virus strains for gene therapy |
CA2466279A1 (en) | 2001-11-13 | 2003-05-22 | Dana-Farber Cancer Institute, Inc. | Agents that modulate immune cell activation and methods of use thereof |
ATE514713T1 (de) | 2002-12-23 | 2011-07-15 | Wyeth Llc | Antikörper gegen pd-1 und ihre verwendung |
EP2161336B2 (en) | 2005-05-09 | 2017-03-29 | ONO Pharmaceutical Co., Ltd. | Human monoclonal antibodies to programmed death 1(PD-1) and methods for treating cancer using anti-PD-1 antibodies alone or in combination with other immunotherapeutics |
AU2006265108C1 (en) | 2005-07-01 | 2013-01-17 | E. R. Squibb & Sons, L.L.C. | Human monoclonal antibodies to programmed death ligand 1 (PD-L1) |
CN102131828B (zh) | 2007-06-18 | 2015-06-17 | 默沙东有限责任公司 | 针对人程序性死亡受体pd-1的抗体 |
EP2262837A4 (en) | 2008-03-12 | 2011-04-06 | Merck Sharp & Dohme | PD-1 BINDING PROTEINS |
WO2010036959A2 (en) | 2008-09-26 | 2010-04-01 | Dana-Farber Cancer Institute | Human anti-pd-1, pd-l1, and pd-l2 antibodies and uses therefor |
KR20210060670A (ko) | 2008-12-09 | 2021-05-26 | 제넨테크, 인크. | 항-pd-l1 항체 및 t 세포 기능을 향상시키기 위한 그의 용도 |
US8741295B2 (en) | 2009-02-09 | 2014-06-03 | Universite De La Mediterranee | PD-1 antibodies and PD-L1 antibodies and uses thereof |
US20110118464A1 (en) * | 2009-11-18 | 2011-05-19 | Kaohsiung Medical University | Halogenated xanthine derivatives and precursors thereof for anti-cancer and anti-metastasis activity and preparing method thereof |
US20130017199A1 (en) | 2009-11-24 | 2013-01-17 | AMPLIMMUNE ,Inc. a corporation | Simultaneous inhibition of pd-l1/pd-l2 |
WO2011082400A2 (en) | 2010-01-04 | 2011-07-07 | President And Fellows Of Harvard College | Modulators of immunoinhibitory receptor pd-1, and methods of use thereof |
US9163087B2 (en) | 2010-06-18 | 2015-10-20 | The Brigham And Women's Hospital, Inc. | Bi-specific antibodies against TIM-3 and PD-1 for immunotherapy in chronic immune conditions |
US8907053B2 (en) | 2010-06-25 | 2014-12-09 | Aurigene Discovery Technologies Limited | Immunosuppression modulating compounds |
EP2710137B1 (en) * | 2011-03-10 | 2018-09-19 | Provectus Pharmatech, Inc. | A combination of rose bengal and anti-ctla4 antibody for use in the treatment of cancer |
EP2591796A1 (en) * | 2011-11-10 | 2013-05-15 | Universität Zürich | Combination medicament comprising IL-12 and an anti-CTLA-4 ligand for tumor therapy |
US10238698B2 (en) * | 2012-01-25 | 2019-03-26 | Dnatrix, Inc. | Biomarkers and combination therapies using oncolytic virus and immunomodulation |
PT3381942T (pt) | 2012-08-30 | 2021-05-24 | Amgen Inc | Método para o tratamento do melanoma que utiliza um vírus herpes simplex e um inibidor de checkpoint imunitário |
JP6895374B2 (ja) * | 2014-07-16 | 2021-06-30 | トランジェーヌTransgene | 免疫チェックポイントモジュレーターの発現用腫瘍溶解性ウイルス |
EP3324988B1 (en) * | 2015-07-20 | 2021-03-03 | Virttu Biologics Limited | Use of oncolytic herpes simplex virus in combination with immune checkpoint inhibitor, in the treatment of cancer |
US20200009204A1 (en) * | 2017-03-15 | 2020-01-09 | Amgen Inc. | Use of oncolytic viruses, alone or in combination with a checkpoint inhibitor, for the treatment of cancer |
-
2013
- 2013-08-30 PT PT181578428T patent/PT3381942T/pt unknown
- 2013-08-30 CN CN201380045105.2A patent/CN104704002B/zh active Active
- 2013-08-30 AU AU2013308595A patent/AU2013308595C1/en active Active
- 2013-08-30 JP JP2015530096A patent/JP6457940B2/ja active Active
- 2013-08-30 EP EP21188061.2A patent/EP3981791A1/en active Pending
- 2013-08-30 ES ES18157842T patent/ES2871910T3/es active Active
- 2013-08-30 CN CN202210427262.0A patent/CN114984062A/zh active Pending
- 2013-08-30 EP EP13760221.5A patent/EP2890714A2/en not_active Withdrawn
- 2013-08-30 US US14/424,424 patent/US10034938B2/en active Active
- 2013-08-30 EA EA201590451A patent/EA201590451A1/ru unknown
- 2013-08-30 EP EP18157842.8A patent/EP3381942B1/en active Active
- 2013-08-30 KR KR1020157005928A patent/KR102204525B1/ko active IP Right Grant
- 2013-08-30 WO PCT/US2013/057542 patent/WO2014036412A2/en active Application Filing
- 2013-08-30 CA CA2881851A patent/CA2881851C/en active Active
- 2013-08-30 KR KR1020217001035A patent/KR20210008155A/ko not_active Application Discontinuation
-
2015
- 2015-12-16 HK HK15112368.2A patent/HK1211601A1/xx unknown
-
2018
- 2018-06-27 US US16/019,753 patent/US20190060452A1/en not_active Abandoned
- 2018-07-24 AU AU2018208640A patent/AU2018208640A1/en not_active Abandoned
- 2018-12-20 JP JP2018238017A patent/JP6656349B2/ja active Active
-
2020
- 2020-02-13 AU AU2020201051A patent/AU2020201051A1/en not_active Abandoned
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RU2802962C2 (ru) * | 2017-10-27 | 2023-09-05 | МЕРК ШАРП И ДОУМ ЭлЭлСи | Композиции и способы лечения рака печени |
Also Published As
Publication number | Publication date |
---|---|
WO2014036412A2 (en) | 2014-03-06 |
KR20210008155A (ko) | 2021-01-20 |
CA2881851A1 (en) | 2014-03-06 |
EP2890714A2 (en) | 2015-07-08 |
JP6457940B2 (ja) | 2019-01-23 |
CN104704002A (zh) | 2015-06-10 |
CN104704002B (zh) | 2022-05-10 |
JP2019065028A (ja) | 2019-04-25 |
JP6656349B2 (ja) | 2020-03-04 |
CA2881851C (en) | 2021-01-26 |
AU2020201051A1 (en) | 2020-03-05 |
KR102204525B1 (ko) | 2021-01-19 |
AU2013308595C1 (en) | 2019-01-17 |
AU2013308595B2 (en) | 2018-04-26 |
US20190060452A1 (en) | 2019-02-28 |
KR20150047512A (ko) | 2015-05-04 |
US10034938B2 (en) | 2018-07-31 |
EP3381942B1 (en) | 2021-04-14 |
HK1211601A1 (en) | 2016-05-27 |
US20150202290A1 (en) | 2015-07-23 |
CN114984062A (zh) | 2022-09-02 |
JP2015526525A (ja) | 2015-09-10 |
AU2018208640A1 (en) | 2018-08-09 |
EP3981791A1 (en) | 2022-04-13 |
WO2014036412A3 (en) | 2014-06-05 |
ES2871910T3 (es) | 2021-11-02 |
EP3381942A1 (en) | 2018-10-03 |
AU2013308595A1 (en) | 2015-03-05 |
PT3381942T (pt) | 2021-05-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EA201590451A1 (ru) | Способ лечения меланомы с применением вируса простого герпеса и ингибитора иммунной контрольной точки | |
HK1247816A1 (zh) | 普那布林聯合免疫檢查點抑制劑的用途 | |
MX2016003129A (es) | Terapia de combinacion de anticuerpos contra el csf-1r humano y anticuerpos contralel pd-l1 humano. | |
ZA202208792B (en) | Methods of treating and preventing graft versus host disease | |
EA201791029A1 (ru) | Антитела против интерлейкина-33 и их применение | |
MX2017010667A (es) | Anticuerpos anti-proteína que contiene domino de inmunologlubina relacionado con el receptor de poliovirus (pvrig) y metodos de unso. | |
EA201590993A1 (ru) | Гетеродимерные иммуноглобулины | |
UY34876A (es) | Anticuerpos anti-egfr y usos de los mismos | |
UY34782A (es) | Anticuerpos humanos para fel d1 y métodos para usarlos. | |
EA201592213A1 (ru) | Антитела антирецептор трансферрина и способы их использования | |
MX2013011479A (es) | Anticuerpos anti-fgfr4 y metodos de uso. | |
CL2016001432A1 (es) | Nuevos anticuerpos anti-dpep3 y métodos de uso | |
MX2015012326A (es) | Anticuerpos anti-crth2 y su uso. | |
EA201490927A1 (ru) | Ингибиторы pak для лечения клеточно-пролиферативных расстройств | |
CR20140212A (es) | Anticuerpos anti-htra1 y métodos de uso | |
EA201691610A8 (ru) | Анти-jagged1 антитела и способы применения | |
EA201591786A1 (ru) | Монотерапия gla для применения в лечении рака | |
UY34675A (es) | ?proceso y aparato para tratar superficies de metal?. | |
MX2016002574A (es) | Nuevos moduladores del homologo 6 (sez6) y metodos de uso. | |
MX354303B (es) | Anticuerpos de anti-biotina y metodos de uso. | |
CL2015002724A1 (es) | Métodos para tratar la enfermedad de crohn utilizando un anticuerpo anti-il23 | |
EA201491357A1 (ru) | Анти-lrp5 антитела и способы их применения | |
UY34124A (es) | Cerramiento y método para conformarlo | |
CR20150585A (es) | Anticuerpos anti-igf-1r con abolición de la unión al fcrn y su utilización en el tratamiento de enfermedades oculares vasculares | |
EP3313186A4 (en) | COMBINATION OF LPT-723 INHIBITORS AND IMMUNE CONTROL POINT AND METHODS OF TREATMENT |